START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2015
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms START
- Sponsors Bayer HealthCare Pharmaceuticals
- 15 Mar 2015 Status changed from active, no longer recruiting to completed according to results published in the International Journal of Cancer.
- 04 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Oct 2009 New trial record